Category: General News
Search News
Results from the Phase I STARPAC trial
24th September 2020
A treatment combination involving the addition of a form of vitamin A to the current standard treatment regimen for pancreatic cancer is safe for patients, according to an early phase clinical trial led by Professor Hemant Kocher from Barts Cancer Institute, Queen Mary University of London.
Read more
Congratulations to Vinaya Srirangam Nadhamuni
22nd September 2020
BCI PhD student wins People’s Choice Award at thesis competition national final Congratulations to Vinaya Srirangam Nadhamuni, Clinical Research Fellow at Barts Cancer Institute (BCI), Queen Mary University of London, […]
Read more
Immunotherapy for advanced bladder cancer
18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more
Investigating new treatment options for mesothelioma
16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more
Prof John Gribben in BBC’s The Diagnosis Detectives
15th September 2020
Professor John Gribben, Lead for the Centre for Haemato-Oncology at Barts Cancer Institute and Consultant Haematologist at Barts Health NHS Trust, is part of a new BBC Two series called The Diagnosis Detectives. Professor Gribben is one of a panel of 12 of the UK’s leading medical experts who have been assembled to diagnose patients with life-changing symptoms that have puzzled other doctors and remained undiagnosed.
Read more
Immune ‘cloaking’ in cancer cells
14th September 2020
Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient’s cancer, helping to guide treatment decisions.
Read more